Chubb and Marsh have teamed up with the World Health Organization (WHO) and Gavi, the Vaccine Alliance, to offer eligible individuals in 92 lower-income countries cover related to adverse effects associated with COVID-19 vaccination.
Marsh led the global placement of the bespoke solution. Chubb is the lead insurer, supported by a further 10 carriers located in several markets in the US, the UK, Germany, Ireland, Switzerland and Bermuda.
The cover relates to rare but serious adverse events associated with vaccines distributed through COVAX up to 30 June 2022. The COVAX No-fault Compensation Program is an international vaccine injury compensation mechanism.
Co-convened by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO, working in partnership with UNICEF, COVAX was created to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee their fair and equitable access for every country in the world.
Under the cover, up to $150 million in insurance is provided for the COVAX No Fault Compensation Program to cover compensation payments to eligible individuals in the 92 lower-income countries and economies, known as the Gavi COVAX Advance Market Commitment (AMC) eligible economies.
The delivery of COVID-19 vaccines during 2021 is expected to be the fastest and largest global deployment of novel vaccines in history.
The COVAX Facility, the global procurement mechanism of COVAX, aims by the end of 2021 to deliver up to 2 billion doses of safe, effective and quality-assured vaccines to all participating countries, including up to 1.7 billion doses to the 92 AMC-eligible countries and economies, at the same time as wealthier nations.
Commenting on the latest move, Evan G Greenberg, chairman and CEO of Chubb, said: “Chubb is pleased to extend our collaboration with the World Health Organization and its partners to support the critically important COVAX No-Fault Compensation Program.”
“The magnitude of the COVID-19 pandemic demands that everyone – from governments and public health authorities to the private sector – bring their skills, capabilities and resources to do their part to end this crisis. We are gratified to work alongside Marsh to support an essential Program that will promote people in all countries, regardless of income levels, having equal access to these life-saving vaccines.”
John Doyle, president and CEO of Marsh, added: “The COVID-19 pandemic is first and foremost a human tragedy, which has resulted in trillions of dollars of economic losses and deeply affected the prospects of some of the world’s poorest countries and their people.
“Throughout the pandemic, Marsh colleagues the world over have worked hard to help clients and communities tackle rapid changes to their risk landscapes. The delivery of COVAX distributed vaccines will now enable some of the most vulnerable societies to rebuild and recover more quickly. By working together, the public sector and insurance industry have the ability to develop solutions that can accelerate economic recovery from COVID-19.”
“The unprecedented nature of the COVID-19 pandemic has been matched by the largest ever rollout of new vaccines under the ACT-Accelerator and its vaccines pillar, COVAX,” said Dr Tedros Adhanom Ghebreyesus, WHO director-general.
“The COVAX No-Fault Compensation Program helps to ensure that people in AMC-eligible countries and economies can benefit from the cutting-edge science that has delivered COVID-19 vaccines in record time.”
“As we implement COVAX, we have worked with all stakeholders towards establishing a comprehensive solution for indemnification that allows novel vaccines to be procured and addresses the financial obligations this may impose on lower-income economies that are part of COVAX,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance.
“The No-Fault Compensation Program is a robust, transparent and an independent mechanism that is going to be a key benefit for individuals being vaccinated and lower-income governments procuring vaccines through the Gavi COVAX AMC,” he added.
This insurance program follows the February agreement between WHO and Chubb, through ESIS, a Chubb company, for the administration of the programme.